Modular Peptide Epitope Vaccine Constructs for Immunocompromised Hosts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for SARS-COV-2 are ineffective in immunocompromised individuals, cause adverse side effects, and are time-consuming and costly to develop, especially for novel pathogens, with limited protection for immunocompromised individuals and unreliable herd immunity.
Innovation Solution
Development of immunogenic constructs comprising scaffold nucleic acid molecules hybridized with complementary nucleic acid molecules conjugated to peptides, specifically antigenic epitopes, and formulated with gold nanoparticles or adjuvants for improved cellular uptake and stability, allowing for modular and rapid vaccine design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines composed of whole pathogens or their components are used, then immune response is induced, but adverse side effects such as vaccine-enhanced infection, toxicity, and inflammatory reactions occur
Solution Approach 1:
The vaccine is segmented into discrete peptide epitopes (e.g., S1 subunit epitopes, RBD epitopes) rather than using whole pathogens. Each epitope is a small, defined segment that specifically targets viral components without including harmful elements of the complete pathogen structure
Solution Approach 2:
Specific protective epitopes are extracted from the viral S protein structure. The invention isolates and uses only the immunogenic epitopic regions (such as those in SEQ ID NOS: 1-8) that induce protective immunity, leaving behind the harmful components of the whole pathogen
2Reliability
If current SARS-COV-2 vaccines are administered, then herd immunity is pursued, but immunocompromised individuals remain at risk due to unreliable herd immunity and inability to mount adequate immune responses
Solution Approach 1:
The vaccine uses modified peptide sequences with optimized parameters for immunogenicity. Specific amino acid substitutions and additions (such as the GSAKFVAAWTLKAAA sequence) are designed to enhance T-helper cell epitope strength and B-cell epitope recognition, creating a more potent immune stimulus that works even in immunocompromised hosts
3Loss of time
If vaccine development is based on prior developed vaccines with modifications, then development time is reduced, but the process remains time-consuming and expensive for novel pathogens
Solution Approach 1:
The invention performs preliminary computational analysis of viral protein sequences to identify potential epitopes before experimental validation. Bioinformatic methods are used in advance to predict immunogenic regions, which accelerates the overall development process by focusing experimental efforts on the most promising candidates
Solution Approach 2:
The vaccine design segments the viral proteome into individual epitope candidates that can be independently evaluated and assembled. This modular approach allows rapid reconfiguration for different viral variants without requiring complete redesign of the entire vaccine platform
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunogenic constructs induce specific immune responses without adverse effects, neutralizing SARS-COV-2 variants, and can be rapidly developed and produced, providing effective protection for immunocompromised individuals and broader populations.
Implementation Method 1
the complementary nucleic acid molecule(s) is hybridized with the scaffold nucleic acid molecule
Data Source
AI summary
Immunogenic constructs and vaccines are provided along with methods of use and manufacture thereof.